New directions in the treatment of B-cell lymphomas

László Tamás (1), Csacsovszky Ottó (2), Bödör Csaba (1)
(1) Semmelweis Egyetem Patológiai és Kísérleti Rákkutató Intézet HCEMM-SE Molekuláris Onkohematológia Kutatócsoport, Budapest
(2) Dél-pesti Centrumkórház – Országos Hematológiai és Infektológiai Intézet, Budapest

Non-Hodgkin’s lymphoma represents a heterogenous group of malignant lymphoproliferative disorders. Over the past decade, the diagnosis and treatment of these diseases have evolved significantly. Advances in molecular methodologies have led to the identification of a plethora of new biomarkers as well as potential therapeutic targets, providing the basis for the advance of the ‘precision medicine’ paradigm-shift in the treatment of haematological malignancies. In this review, we provide an overview of the genetic background and tumour microenvironment of the three most common non-Hodgkin’s lymphomas, follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) with special emphasis on the new therapeutic modalities based on these findings.